Proactive Investors - Run By Investors For Investors

Advaxis encouraged by new cancer-fighting drug data as the company gears up for clinical trials

Phase 1 clinical trials are about to begin on its primary neoantigen, or tumor-directed therapy, ADXS-NEO
The Princeton, New Jersey-based company is focused on treatments that boosts the body's natural defenses to fight cancer

Advaxis Inc (NASDAQ:ADXS) is encouraged by favorable data from its new cancer immunotherapy treatment that demonstrated tumor-fighting properties, it said in a note Monday.

The Princeton, New Jersey-based company is focused on the discovery, development and commercialization of treatments that boosts the body's natural defenses to fight cancer.

Phase 1 clinical trials are about to begin on its primary neoantigen, or tumor-directed therapy, ADXS-NEO. In preliminary data, the treatment demonstrated anti-tumor immune activation within one week after the first dose.

READ: ImmunoPrecise signs up a slew of new pharma clients for its antibody-discovering phage display platform

CEO Kenneth Berlin said in a statement that the results fuel Advaxis’s belief that neoantigen-directed immunotherapies can become an important addition to the cancer treatment paradigm due to the unique presentation of neoantigens in cancer cells.

“The results from our ADXS-NEO program have shown the ability to have an impact within the tumor microenvironment in metastatic colorectal cancer, which historically has been a tumor type that is refractory to immunotherapy,” he said. “We look forward to starting Part B of the study with ADXS-NEO in combination with a checkpoint inhibitor in the third quarter of this year.”

During fiscal 2Q ending April 30, 2019, the biotechnology company reported total revenue of $1.2 million compared to the $1.7 million in 2Q 2018. Advaxis said the decrease was due to the termination of a collaboration with biopharmaceutical company Amgen.

Net loss for the second quarter of 2Q 2019 was $9.4 million or $1.59 per share, compared with a loss of $13.4 million or $4.03 per share during the year-ago quarter.

The company said it is in discussions with a leading academic institution to finalize an investigator-sponsored trial evaluating ADXS-HOT in patients with prostate cancer and anticipate filing an Investigational New Drug application with the US Food and Drug Administration later this year.

Shares of Advanxis lost 10.7% in aftermarket trading to sit at $2.50.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full ADXS profile View Profile

Advaxis Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use